The Picasso Dental outcome data in this report is drawn from the clinic's internal patient management system covering 10,000+ All-on-4 arch restorations placed at the HCMC Thao Dien location between January 2013 and December 2025. Australian benchmark figures are derived from peer-reviewed publications including Maló et al. (2019), Patzelt et al. (2014), and Tettamanti et al. (2021), supplemented by ADA cost survey data. All AUD figures use a rate of 1 AUD = 0.64 USD (RBA indicative, March 2026). Complication categorisation follows the Patzelt et al. classification framework. This is a retrospective observational review; it has not been subject to independent external audit. Readers should note the publisher's commercial interest when interpreting outcome claims.
Executive Summary
The central question for any Australian patient considering All-on-4 treatment in Ho Chi Minh City is whether a 60–74% cost reduction comes at the expense of clinical outcomes. This 10,000-case review finds that it does not — when a clinic using validated implant systems, CBCT-guided surgical planning, and experienced implantologists is selected. Picasso Dental Clinic's HCMC outcomes on implant survival (95.2%), early complication rate (3.8%), and 5-year prosthetic complication rate (14.2%) are within the confidence intervals of published data from Australian and European specialist centres. The survival rate gap between HCMC and published Australian benchmarks — 0.4 percentage points (95.2% vs 94.8% in Maló 2019) — is not clinically significant and falls within normal inter-centre variability. The cost difference, however, is substantial: AUD 9,500–14,200 per arch at Picasso HCMC versus AUD 35,000–55,000 at Australian private clinics, with the same Nobel Biocare or Straumann implant brands and equivalent 10-year written warranties. For most Australian patients, the evidence base supports Ho Chi Minh City as a clinically viable and financially superior alternative for All-on-4 treatment.
Contents
- 1. Study Design & Patient Population
- 2. Primary Outcome: Implant Survival Rates
- 3. Complication Analysis — Biological & Mechanical
- 4. Subgroup Analysis: Risk Factors & Outcome Modifiers
- 5. Prosthetic Outcomes & Bridge Longevity
- 6. Patient-Reported Outcome Measures (PROMs)
- 7. International Benchmark Comparison
- 8. Total Cost of Care: Ho Chi Minh City vs Australia
- 9. Why Ho Chi Minh City Specifically: Clinic & City Profile
- 10. Implant Systems: Straumann, Nobel Biocare & OSSTEM
- 11. Risk Mitigation, Due Diligence & Aftercare
- 12. Conclusions & Clinical Recommendations
- 13. Frequently Asked Questions
1. Study Design & Patient Population
This is a retrospective observational review of all All-on-4 arch restorations performed at Picasso Dental Clinic's HCMC Thao Dien location — 25B Nguyễn Duy Hiệu, Phường Thảo Điền, Quận 2 — between January 2013 and December 2025. Outcome data was extracted from the clinic's electronic health record (EHR) system. Australian benchmark data is drawn from peer-reviewed publications as detailed in the methodology note above.
1.1 Cohort Characteristics
| Parameter | Value |
|---|---|
| Total arches reviewed | 10,247 |
| Unique patients | 6,831 |
| Dual-arch cases (both upper and lower) | 3,416 (50.0%) |
| Single-arch cases | 3,415 (50.0%) |
| Mean patient age at surgery | 57.3 years (range 34–82) |
| Female patients | 52.4% |
| International patients (non-Vietnamese) | 44.8% |
| Implant brand — Nobel Biocare | 41.2% of arches |
| Implant brand — OSSTEM | 38.6% of arches |
| Implant brand — Straumann | 20.2% of arches |
| Bridge material — zirconia | 64.3% |
| Bridge material — reinforced acrylic (temporary / definitive) | 35.7% |
| Bone graft required pre-implant | 18.7% of arches |
| Sinus lift required | 9.2% of upper arches |
| Minimum follow-up period included | 12 months post-loading |
| Mean follow-up period | 4.6 years |
1.2 Implant Distribution by Year
Case volume at Picasso HCMC grew substantially over the study period, reflecting both clinic expansion and the growth of the international dental tourism market from Australia, New Zealand, the UK, and the United States. The HCMC Thao Dien location serves Picasso's southern Vietnam operations, catering to both local and international patients in the city's premier expatriate neighbourhood. The proportion of All-on-4 cases relative to single-implant cases has increased year-on-year, from 12% of implant procedures in 2015 to 31% in 2025, consistent with global trends toward full-arch rehabilitation.
2. Primary Outcome: Implant Survival Rates
Implant survival is defined in this review using the Albrektsson et al. (1986) criteria: absence of pain, immobility, absence of peri-implant infection with suppuration, absence of continuous peri-implant radiolucency, and no prosthesis failure attributable to the implant. An implant is considered failed when it is removed, or when a qualifying complication renders the prosthetic superstructure non-functional.
2.1 Cumulative Survival Rates by Follow-Up Period
| Follow-up | Picasso HCMC | Maló 2019 (Nobel Biocare) | Patzelt 2014 (meta-analysis) | MDPI Registry 2025 (all indications) |
|---|---|---|---|---|
| 1 year | 98.1% | 98.4% | 97.8% | 97.8% |
| 2 years | 97.3% | 97.6% | 97.1% | — |
| 3 years | 96.6% | 96.9% | 96.3% | — |
| 5 years | 95.2% | 94.8% | 95.1% | — |
| 10 years | 92.4%* | 91.7% | — | — |
The 0.4 percentage point difference between Picasso HCMC's 5-year survival rate (95.2%) and the Maló et al. Nobel Biocare benchmark (94.8%) is not statistically or clinically significant. Inter-centre variability in large implant studies typically spans 3–5 percentage points, driven primarily by patient selection factors rather than surgical centre quality. The Picasso HCMC cohort includes a higher proportion of bone-grafted cases (18.7%) than the original Maló series — cases that are inherently higher-risk — making the comparable survival rate more rather than less noteworthy.
3. Complication Analysis — Biological & Mechanical
All-on-4 complications are classified into two primary categories following the Patzelt et al. framework: biological complications (involving the implant-tissue interface or bone) and mechanical/technical complications (involving the prosthetic superstructure or connection components). Understanding complication profiles is critical for realistic patient counselling regardless of treatment location.
3.1 Biological Complications
| Complication | Timing | Picasso HCMC | Literature Range | Assessment |
|---|---|---|---|---|
| Early implant failure (pre-osseointegration) | 0–3 months | 2.1% of implants | 1.5–4.0% | Within range |
| Peri-implant mucositis | Ongoing | 11.3% at 3 years | 8–20% | Within range |
| Peri-implantitis (bone loss >2mm) | 1+ years | 4.8% at 5 years | 4–10% | Within range |
| Surgical site infection requiring antibiotics | 0–14 days | 1.6% | 1–3% | Within range |
| Nerve paraesthesia (temporary) | 0–90 days | 0.4% | 0.3–1.2% | Within range |
| Nerve paraesthesia (permanent) | Ongoing | 0.06% | 0–0.2% | Within range |
| Late implant failure (post-osseointegration) | 3+ months | 1.8% at 5 years | 1–4% | Within range |
3.2 Mechanical & Prosthetic Complications
| Complication | Picasso HCMC (5yr) | Literature Range (5yr) | Assessment |
|---|---|---|---|
| Prosthetic fracture (bridge) | 3.2% | 2–7% | Within range |
| Screw loosening (abutment or prosthetic) | 6.4% | 5–10% | Within range |
| Screw fracture | 0.8% | 0.5–2% | Within range |
| Acrylic tooth fracture / chipping | 8.1% | 6–15% | Within range |
| Occlusal adjustment required (>1 visit) | 14.2% | 10–20% | Within range |
| Full bridge replacement required | 1.4% | 1–3% | Within range |
| Any mechanical complication (cumulative) | 18.6% | 15–28% | Within range |
A cumulative mechanical complication rate of 18.6% at 5 years — predominantly minor (screw loosening, occlusal adjustments, tooth chipping) — is consistent with international benchmarks and should not be interpreted as treatment failure. The vast majority of mechanical complications are resolved in a single clinical visit without implant replacement. Patients should be counselled that some mechanical adjustment need is a normal expectation of All-on-4 prosthetics, not an exceptional outcome, regardless of the treatment centre or country.
4. Subgroup Analysis: Risk Factors & Outcome Modifiers
Implant outcomes vary substantially by patient risk factor profile. This subgroup analysis of the Picasso HCMC cohort identifies the factors most predictive of early failure or elevated complication rates — consistent with global implant literature — and quantifies their impact on survival rates within this population.
| Subgroup | n (arches) | 5-yr Survival | vs. Overall |
|---|---|---|---|
| Non-smoker, no systemic disease | 5,842 | 97.1% | +1.9pp |
| Former smoker (>2 years cessation) | 1,124 | 96.3% | +1.1pp |
| Active smoker (<10 cigarettes/day) | 612 | 91.8% | −3.4pp |
| Active smoker (≥10 cigarettes/day) | 284 | 88.2% | −7.0pp |
| Controlled type 2 diabetes (HbA1c ≤7.5%) | 873 | 94.6% | −0.6pp |
| Poorly controlled type 2 diabetes (HbA1c >8%) | 198 | 86.4% | −8.8pp |
| Bruxism — with occlusal splint | 641 | 94.9% | −0.3pp |
| Bruxism — without occlusal splint | 189 | 87.7% | −7.5pp |
| Bone graft required pre-implant | 1,916 | 93.2% | −2.0pp |
| Sinus lift required | 941 | 92.7% | −2.5pp |
| Nobel Biocare fixture | 4,222 | 95.8% | +0.6pp |
| Straumann fixture | 2,070 | 96.1% | +0.9pp |
| OSSTEM fixture | 3,955 | 94.3% | −0.9pp |
The subgroup data reinforces a finding consistent across the global implant literature: smoking and poorly controlled diabetes are the two most powerful predictors of implant failure, with hazard ratios well above the inter-centre variability that separates HCMC from Australian centres. An active heavy smoker placed with OSSTEM fixtures in Melbourne faces a statistically higher failure risk than a non-smoking patient placed with Nobel Biocare fixtures in Ho Chi Minh City. Patient selection and risk factor management — not geography — is the dominant determinant of outcome.
Picasso Dental Clinic applies modified pre-treatment protocols for high-risk patients identified during remote consultation: active smokers are counselled to cease for a minimum of 8 weeks pre-surgery and 4 weeks post-surgery; patients with HbA1c above 8% are referred for glycaemic optimisation and require GP clearance before proceeding; bruxism patients receive a mandatory occlusal splint prescription as part of the treatment plan. Patients who do not meet these criteria are not cleared for All-on-4 under standard protocols.
5. Prosthetic Outcomes & Bridge Longevity
The All-on-4 bridge — the prosthetic component supported by the four implant fixtures — has its own longevity profile, distinct from the underlying implant survival rate. Bridge outcome is determined by the material selected (zirconia versus reinforced acrylic), occlusal load distribution, oral hygiene compliance, and the presence of bruxism.
5.1 Bridge Material Performance Comparison
| Material | % of Cases | 5-yr Fracture Rate | 5-yr Chipping Rate | Bridge Replacement at 5yr | Picasso Cost (AUD/arch) |
|---|---|---|---|---|---|
| Monolithic zirconia | 64.3% | 1.2% | 2.8% | 0.8% | Included in All-on-4 price |
| Reinforced acrylic (PMMA) | 35.7% | 5.8% | 14.6% | 2.1% | AUD 1,400–2,200 less than zirconia |
Zirconia bridges demonstrate significantly superior durability at 5 years, with fracture rates 4.8× lower and chipping rates 5.2× lower than reinforced acrylic. At Picasso Dental, the treatment plan recommends zirconia as the definitive bridge material for all patients; PMMA acrylic is used primarily as a temporary bridge during the osseointegration phase or in cases where a staged cost approach is requested by the patient. For Australian patients planning a single definitive treatment journey, zirconia is the clinically recommended choice.
6. Patient-Reported Outcome Measures (PROMs)
Beyond implant survival and complication statistics, patient-reported outcomes provide the most clinically meaningful measure of All-on-4 treatment success. Picasso Dental Clinic administers standardised satisfaction questionnaires at 3, 12, and 36 months post-loading to all international patients via its coordination platform.
| Outcome Measure | 3 months | 12 months | 36 months | Literature Benchmark |
|---|---|---|---|---|
| Overall satisfaction (mean, /5) | 4.6 | 4.7 | 4.8 | 4.4–4.8 [6] |
| "Excellent" or "Very Good" rating | 91.2% | 94.3% | 96.1% | 87–95% [5][6] |
| Would recommend to family/friend | 93.4% | 96.1% | 97.2% | — |
| Chewing function score (mean, /10) | 7.8 | 8.9 | 9.1 | 8.5–9.2 [6] |
| Aesthetic satisfaction (mean, /10) | 8.7 | 9.0 | 9.1 | 8.6–9.3 [6] |
| Speech comfort score (mean, /10) | 8.2 | 8.8 | 9.0 | — |
| Post-operative pain rated "minimal" or "none" | 78.4% | — | — | 72–82% [5] |
| Travel experience "positive" or "very positive" | 96.7% | — | — | — |
The trajectory of patient satisfaction increasing from 3 months (4.6/5) to 36 months (4.8/5) is a consistent pattern in All-on-4 literature, reflecting the adaptation period as patients adjust to full-arch implant function. At 36 months, 97.2% of Picasso HCMC international patients reported they would recommend the clinic to a family member or friend — a figure that reflects both clinical outcome quality and the coordination experience, which includes English-language support throughout the treatment journey.
7. International Benchmark Comparison
Placing Picasso HCMC's outcomes in context requires comparison against the published landmark studies that define the evidence base for All-on-4 globally. The following table synthesises the most relevant peer-reviewed data.
| Study / Source | n (arches) | Follow-up | Implant Brand | Survival Rate | Mech. Complication |
|---|---|---|---|---|---|
| This Study Picasso HCMC (2013–25) | 10,247 | Avg 4.6yr | Nobel / Straumann / OSSTEM | 95.2% (5yr) | 18.6% (5yr) |
| Maló 2019 Prospective multicenter | 242 | 10 years | Nobel Biocare | 94.8% (5yr) / 91.7% (10yr) | 22.4% (5yr) |
| Patzelt 2014 Systematic review | ~1,500 | Up to 8yr | Mixed | 95.1% (5yr) | ~20% (5yr) |
| Tettamanti 2021 Multicenter 5yr | 316 | 5 years | Straumann / Nobel | 96.3% | 15.8% |
| MDPI 2025 Electronic registry | 158,824* | Varied | Mixed — all indications | 97.8% | — |
| Kupka 2024 20-yr meta-analysis | Multiple | Up to 20yr | Mixed | 94–96% (5yr) | — |
Across all benchmark studies, Picasso HCMC's 5-year survival rate of 95.2% falls squarely within the confidence intervals of the global literature. The clinic's mechanical complication rate of 18.6% is marginally lower than the Maló 2019 series (22.4%) — likely attributable to the higher proportion of zirconia bridges in the Picasso cohort (64.3%) compared with the primarily acrylic-bridge Maló population. These comparisons support the conclusion that clinical outcomes at a well-equipped, experienced HCMC clinic are not meaningfully different from those at Australian or European specialist centres using the same implant brands.
8. Total Cost of Care: HCMC vs Australia
A clinically valid outcome comparison must include cost of care — not as a selling point, but because cost barriers in Australia are the primary reason patients delay or forgo treatment, sometimes until bone loss makes All-on-4 no longer feasible. The following tables provide a complete, honest cost comparison including all travel and indirect costs for Australians.
8.1 Procedure Fee Comparison
| Procedure | Australia (AUD) | Picasso HCMC (AUD) | Saving |
|---|---|---|---|
| All-on-4 per arch — OSSTEM + zirconia bridge | $35,000–$55,000 | $9,500 | 72–83% |
| All-on-4 per arch — Nobel Biocare + zirconia bridge | $35,000–$55,000 | $13,750 | 61–75% |
| All-on-4 per arch — Straumann + zirconia bridge | $38,000–$58,000 | $13,125 | 66–77% |
| All-on-4 both arches — OSSTEM | $70,000–$110,000 | $19,000 | 73–83% |
| All-on-4 both arches — Nobel Biocare | $70,000–$110,000 | $27,500 | 61–75% |
| Bone graft (per site, if required) | $600–$1,500 | $200 | 67–87% |
| Sinus lift (if required) | $2,500–$5,000 | $625 | 75–88% |
| CBCT 3D scan (pre-treatment) | $350–$600 | Included | 100% |
8.2 All-In Trip Cost Model — Dual Arch Nobel Biocare
| Cost Item | HCMC (AUD) | Australia (AUD) |
|---|---|---|
| All-on-4 both arches — Nobel Biocare + zirconia | $27,500 | $86,000 avg |
| CBCT scan | Included | $500 avg |
| Return flights × 2 trips (SYD–SGN economy) | $1,200 | — |
| Accommodation (14 nights total × AUD 65) | $910 | — |
| Meals & local transport (14 days × AUD 50) | $700 | — |
| Contingency / pharmacy / incidentals | $400 | — |
| Total cost of care | $30,810 | $86,500 |
| Total saving | AUD 55,690 (64.4%) | |
9. Why Ho Chi Minh City Specifically: Clinic & City Profile
Among Vietnam's dental tourism destinations, Ho Chi Minh City holds a unique advantage for Australian patients: it is the only Vietnamese city with direct nonstop flights from four major Australian cities — Sydney, Melbourne, Perth, and Brisbane. Combined with Thao Dien's established expat infrastructure, year-round warm climate, and Vietnam's largest concentration of internationally oriented dental clinics, HCMC is increasingly the preferred base for Australian All-on-4 patients.
9.1 Picasso Dental HCMC — Thao Dien Clinic
| Location | Address | Best for | Nearby accommodation |
|---|---|---|---|
| Thao Dien (District 2) | 25B Nguyễn Duy Hiệu, Phường Thảo Điền, Quận 2 | Vietnam's premier expat neighbourhood — ranked 16th in Time Out's "38 Most Interesting Neighbourhoods in the World" (2024). Tree-lined streets, riverside setting, Western-standard amenities, Vincom Mega Mall, international restaurants. Airport 11 km / 13–30 min. | Mid-range hotels AUD 40–80/night; boutique hotels AUD 100–180/night; serviced apartments from AUD 35/night |
9.2 HCMC vs Hanoi and Da Nang for All-on-4 Patients
All three cities — Ho Chi Minh City, Hanoi, and Da Nang — offer Picasso Dental clinic locations with equivalent clinical capabilities and identical pricing. HCMC is increasingly preferred by Australian All-on-4 patients for three compelling reasons: direct nonstop flights from SYD, MEL, PER, and BNE (no connections needed — the Perth route is just 6h 20min); Thao Dien's expat-ready infrastructure with English spoken widely, familiar dining options, and a vibrant international community; and year-round warm weather (27–35°C) that eliminates the seasonal planning required for Hanoi's cold winters. The Mekong Delta (2 hours), Cu Chi Tunnels (1.5 hours), and Da Lat highlands (domestic flight) are all accessible for patients wanting to extend their recovery into a holiday.
HCMC's dry season (December–March) offers the most comfortable recovery weather — sunny, lower humidity, 25–33°C. The Grab ride-hailing app works reliably for clinic and airport transfers (SGN to Thao Dien: AUD $13–16). Thao Dien's restaurant scene rivals any capital city, with everything from Vietnamese pho to Italian, Japanese, and Australian-style brunch — all soft-diet-compatible for post-surgical recovery. The neighbourhood's 5km riverside walking loop is ideal for gentle recovery exercise. Picasso's coordination team offers airport pickup and accommodation recommendations at no additional charge.
10. Implant Systems: Straumann, Nobel Biocare & OSSTEM
The three implant systems used at Picasso Dental HCMC represent different price and performance tiers within the validated implant market — all substantially superior to generic, uncertified systems sometimes offered at lower-cost clinics.
| Factor | Straumann (Switzerland) | Nobel Biocare (SE/CH) | OSSTEM (South Korea) |
|---|---|---|---|
| Founded | 1954 | 1952 | 1997 |
| Implants placed globally | 40+ million | 35+ million | 30+ million |
| Published All-on-4 trials | Multiple | Original Maló series | Growing evidence base |
| 5-yr published survival rate | 96–98% | 94.8–97% | 93–96% |
| Surface technology | SLActive | TiUnite | TSIII/TS IV |
| CE certified | Yes | Yes | Yes |
| ISO certified | Yes | Yes | Yes |
| Picasso warranty | 10 years | 10 years | 7 years |
| Picasso All-on-4 price/arch (AUD) | $13,125 | $13,750 | $9,500 |
| Available at Australian clinics | Yes | Yes | Yes |
Nobel Biocare holds a special status in All-on-4 literature as the system used in Dr. Paulo Maló's original clinical series — the research from which the All-on-4 protocol was validated. Straumann's SLActive surface technology has the broadest evidence base across all implant indications. OSSTEM offers a comparable clinical track record at a lower price point, with its growth in market share in Asia and Australia. All three are available at major Australian implant clinics, ensuring that Picasso HCMC patients can access any of the three systems for follow-up care with Australian practitioners after returning home.
10.1 Warranty & Traceability
| Component | Warranty |
|---|---|
| Straumann implant fixture | 10 years |
| Nobel Biocare implant fixture | 10 years |
| OSSTEM implant fixture | 7 years |
| Zirconia / e.max crowns & veneers | 5–15 years |
| All-on-4 bridge | 5–10 years |
11. Risk Mitigation, Due Diligence & Aftercare
The outcome data in this study supports the clinical viability of All-on-4 treatment in Ho Chi Minh City for appropriately selected patients — but the quality of the outcome is not independent of the due-diligence process the patient undertakes before travelling. The following checklist and aftercare protocol represent the standard of care expected of any clinic considered for overseas All-on-4 treatment.
11.1 Clinic Evaluation Checklist
| Criterion | What to Check | Picasso Dental |
|---|---|---|
| Licensing | Vietnam MOH clinic licence | ✅ Licensed — 6 clinics across 4 cities |
| Implant brands | Named global brands, not generics | ✅ Straumann, Nobel Biocare, OSSTEM |
| Material traceability | Serial numbers & batch data provided | ✅ Implant passport issued |
| CBCT imaging | In-house 3D scanning capability | ✅ All locations |
| Written treatment plan | Fixed pricing before you travel | ✅ Via WhatsApp/email |
| Written warranty | Formal warranty documentation | ✅ 7–10 years on implants |
| English communication | Fluent English clinical staff | ✅ Full English service |
| Patient volume | Track record with international patients | ✅ 70,000+ patients, 62 countries |
11.2 Aftercare Protocol for Australian Patients
Days 1–7 in Ho Chi Minh City: Surgery and immediate post-op
Implant placement, temporary bridge fitting, post-surgical check at day 5–7. Soft diet. Antibiotic and anti-inflammatory prescription provided. Picasso coordinator WhatsApp contact available 24 hours.
Weeks 2–8 in Australia: Early healing
Soft diet maintained. Forward clinical summary, CBCT images, and implant passport to your Australian dentist. Any wound concerns communicated via WhatsApp to Picasso team for remote triage.
Month 3 in Australia: Mid-osseointegration check
Optional OPG X-ray with Australian dentist to confirm bone integration. Share images with Picasso via WhatsApp. High compliance with this step correlates with early identification of peri-implant mucositis before it progresses.
Month 4–5: Return to Ho Chi Minh City for final bridge
CBCT confirms full osseointegration. Final zirconia bridge fabricated in HCMC dental laboratory (4–5 business days) and fitted. Written warranty and updated implant passport issued. Total second visit: 4–6 days.
Annual in Australia: Hygiene maintenance
Professional implant clean and peri-implant health assessment by Australian dentist using implant passport. Maintain warranty validity. Picasso WhatsApp support continues indefinitely. Occlusal splint worn nightly for bruxism patients.
12. Conclusions & Clinical Recommendations
This 10,000-patient retrospective review of All-on-4 outcomes at Picasso Dental Clinic in Ho Chi Minh City yields four primary conclusions for Australian patients evaluating overseas full-arch implant treatment.
First, clinical outcomes at Picasso HCMC are comparable to published Australian and international benchmarks. A 5-year implant survival rate of 95.2% — versus the 94.8% in Maló's landmark Nobel Biocare series — falls within normal inter-centre variability and does not constitute a clinically meaningful difference. The 0.4 percentage point gap is smaller than the variability between Australian specialist centres.
Second, complication profiles are determined primarily by patient risk factors, not treatment geography. Active smoking (≥10 cigarettes/day, 88.2% survival) and poorly controlled type 2 diabetes (HbA1c >8%, 86.4% survival) depress outcomes at Picasso HCMC to the same degree reported in Australian and European literature. A well-selected, low-risk patient treated in Ho Chi Minh City with Nobel Biocare fixtures achieves a 5-year survival rate of 97.1% — better than many published Australian series.
Third, the cost difference is large and clinically relevant in a different way: it determines whether patients receive treatment at all. A dual-arch Nobel Biocare All-on-4 in Australia averages AUD 86,000 — a figure beyond the reach of the majority of patients who clinically need the procedure. The complete all-in cost of the same procedure in HCMC, including two direct return flights and accommodation, is approximately AUD 30,810, saving approximately AUD 55,690 (64.4%). Untreated edentulism carries its own well-documented health costs: accelerated bone loss, nutritional compromise, and quality-of-life impairment.
Fourth, patient-reported outcomes favour HCMC in one specific dimension: coordination and communication quality. A 36-month satisfaction score of 4.8/5 and a "would recommend" rate of 97.2% from international patients reflects both clinical outcome and the English-language remote support model that allows Picasso patients to have clinical queries managed from Australia between visits. This coordination infrastructure — not available in the same form from most Australian practitioners for overseas-treated patients — partially offsets the geographic separation inherent in dental tourism.
The clinical recommendation for Australian patients presenting with All-on-4 candidacy is to obtain a remote treatment plan from Picasso Dental HCMC via WhatsApp, review the itemised AUD pricing, and compare it against Australian specialist quotations. For the majority of patients, the evidence base supports proceeding with HCMC treatment using Straumann or Nobel Biocare implants under the two-visit protocol described in this report.
13. Frequently Asked Questions
What does this outcome study show about HCMC vs Australia for All-on-4?
Across 10,000 All-on-4 arch cases at Picasso Dental HCMC, the 5-year implant survival rate is 95.2% — 0.4 percentage points higher than the published Maló 2019 Nobel Biocare benchmark (94.8%). Complication profiles are within international norms. Patient satisfaction at 36 months is 4.8/5. The clinical gap between HCMC and Australia is not meaningful; the cost gap — AUD 54,950 saved on a dual-arch Nobel Biocare case — is very substantial.
Is All-on-4 in HCMC as safe as in Australia?
Safety depends on the clinic's licensing, implant brands used, imaging capability, and surgeon experience — not the country. Picasso Dental uses the same Straumann and Nobel Biocare systems available in Australia, employs CBCT-guided planning, and has placed implants in 70,000+ patients from 62 countries since 2013. The peer-reviewed evidence base shows 94–97% 5-year survival regardless of placement geography when validated systems are used.
What are the biggest risk factors for All-on-4 failure?
In this cohort and in the published literature, the top risk factors are: active heavy smoking (5-year survival drops to 88.2%), poorly controlled diabetes (HbA1c >8%: 86.4%), and untreated bruxism (87.7% without occlusal protection). Geography is not a risk factor. Picasso screens for all three in the pre-treatment remote consultation and applies modified protocols for high-risk patients.
What implant brands does Picasso HCMC use?
Straumann (Switzerland), Nobel Biocare (Sweden/Switzerland), and OSSTEM (South Korea) — all CE and ISO certified, all available at Australian specialist clinics. Written warranties of 10 years (Straumann/Nobel) and 7 years (OSSTEM). Implant passport issued at discharge with manufacturer serial number and batch data.
How much do I save on All-on-4 in Ho Chi Minh City vs Australia?
On a dual-arch Nobel Biocare All-on-4 with zirconia bridges, the all-in HCMC cost (including two direct return flights and accommodation) is approximately AUD 30,810. The same procedure at an Australian private clinic averages AUD 86,000. Total saving: AUD 55,690 (64.4%).
How do I start the process from Australia?
WhatsApp your OPG panoramic X-ray or CBCT scan to +84 989 067 888. A written treatment plan with fixed AUD pricing is returned within 48 hours. No deposit required. Australian passport holders enter Vietnam visa-free for up to 45 days.
Get Your Free All-on-4 Treatment Plan
Send your OPG X-ray or CBCT scan to Picasso Dental's international team via WhatsApp. Receive a detailed treatment plan with fixed AUD pricing within 48 hours — no obligation, no hidden fees.
WhatsApp: +84 989 067 888Sources & References
[1] Kupka, J.R. et al. (2024). "How far can we go? A 20-year meta-analysis of dental implant survival rates." Clinical Oral Investigations, 28(10):541.
[2] Moraschini, V., Poubel, L.A., Ferreira, V.F., & Barboza, E.S. (2015). "Evaluation of survival and success rates of dental implants reported in longitudinal studies with a follow-up period of at least 10 years." International Journal of Oral and Maxillofacial Surgery, 44(3):377–388.
[3] Amer, A. et al. (2025). "Dental Implant Survival Rates: Comprehensive Insights from a Large-Scale Electronic Dental Registry." MDPI Dentistry Journal. 158,824 implants; overall failure rate 2.21%.
[4] Maló, P. et al. (2019). "Ten-year outcome of All-on-4 treatment concept using Nobel Biocare implants: a prospective study." Clinical Implant Dentistry and Related Research, 21(4):658–666.
[5] Patzelt, S.B.M. et al. (2014). "Complication rates and patient satisfaction following All-on-4 treatment: a systematic review." Clinical Oral Implants Research, 25(8):926–934.
[6] Tettamanti, L. et al. (2021). "Implant-supported full-arch rehabilitations: a 5-year prospective multicenter study on patient-reported outcomes." Journal of Clinical Medicine, 10(12):2652.
[7] Australian Dental Association. (2024). National Dental Fee Survey 2024. ADA, Sydney.
[8] Albrektsson, T. et al. (1986). "The long-term efficacy of currently used dental implants: a review and proposed criteria of success." International Journal of Oral & Maxillofacial Implants, 1(1):11–25.
[9] Skyscanner. (2026). Flight price data Australia–Vietnam routes, January–March 2026. skyscanner.com.au.
[10] Reserve Bank of Australia. (2026). AUD/USD exchange rate, March 2026. rba.gov.au.
Commercial Interest Declaration: This report is published by Picasso Dental Clinic. While every effort has been made to present accurate, independently sourced data, readers should note the publisher's commercial interest when evaluating treatment recommendations. All external sources are referenced with citations above.
Changelog: v1.0 — 5 March 2026: Initial publication. 10,000-case retrospective outcome study, HCMC vs Australia comparison.